On the surface, sanofi-aventis'
Below the surface? Who knows; the top-line result is all Sanofi gave us. In an announcement today, the company said teriflunomide met its primary goal of reducing the annualized relapse rate compared to placebo. But given that there were only four sentences of non-background information, that's about all we know. We'll know more once the full data set is presented at a scientific meeting in October.
Sanofi is behind Novartis
Being third or even fourth to the market isn't disastrous, in this case. The current offerings from Biogen Idec
Plus, Novartis' and Merck KGaA's drug both have side effect issues that probably won't keep them off the market, but could make them vulnerable to competition. In its press release, Sanofi said that both doses of teriflunomide had "similar number" of adverse events compared to placebo. That certainly sounds positive, but we'll have to wait until the full data is released before we know exactly how similar they are.
Today's announcement appears to be positive for Sanofi and potentially negative for Novartis and Merkc KGaA, but until we see the full data set, it's a little hard to get all that excited.
Matthew Argersinger is excited about this one; excited about how bad it's doing, that is.